COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy

Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaledi, Mansoor, Sameni, Fatemeh, Yahyazade, Sheida, Radandish, Maedeh, Owlia, Parviz, Bagheri, Nader, Afkhami, Hamed, Mahjoor, Mohamad, Esmaelpour, Zahra, Kohansal, Maryam, Aghaei, Farzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469902/
https://www.ncbi.nlm.nih.gov/pubmed/36111104
http://dx.doi.org/10.3389/fmed.2022.961027
_version_ 1784788735712296960
author Khaledi, Mansoor
Sameni, Fatemeh
Yahyazade, Sheida
Radandish, Maedeh
Owlia, Parviz
Bagheri, Nader
Afkhami, Hamed
Mahjoor, Mohamad
Esmaelpour, Zahra
Kohansal, Maryam
Aghaei, Farzad
author_facet Khaledi, Mansoor
Sameni, Fatemeh
Yahyazade, Sheida
Radandish, Maedeh
Owlia, Parviz
Bagheri, Nader
Afkhami, Hamed
Mahjoor, Mohamad
Esmaelpour, Zahra
Kohansal, Maryam
Aghaei, Farzad
author_sort Khaledi, Mansoor
collection PubMed
description Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors.
format Online
Article
Text
id pubmed-9469902
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94699022022-09-14 COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy Khaledi, Mansoor Sameni, Fatemeh Yahyazade, Sheida Radandish, Maedeh Owlia, Parviz Bagheri, Nader Afkhami, Hamed Mahjoor, Mohamad Esmaelpour, Zahra Kohansal, Maryam Aghaei, Farzad Front Med (Lausanne) Medicine Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9469902/ /pubmed/36111104 http://dx.doi.org/10.3389/fmed.2022.961027 Text en Copyright © 2022 Khaledi, Sameni, Yahyazade, Radandish, Owlia, Bagheri, Afkhami, Mahjoor, Esmaelpour, Kohansal and Aghaei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Khaledi, Mansoor
Sameni, Fatemeh
Yahyazade, Sheida
Radandish, Maedeh
Owlia, Parviz
Bagheri, Nader
Afkhami, Hamed
Mahjoor, Mohamad
Esmaelpour, Zahra
Kohansal, Maryam
Aghaei, Farzad
COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
title COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
title_full COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
title_fullStr COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
title_full_unstemmed COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
title_short COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
title_sort covid-19 and the potential of janus family kinase (jak) pathway inhibition: a novel treatment strategy
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469902/
https://www.ncbi.nlm.nih.gov/pubmed/36111104
http://dx.doi.org/10.3389/fmed.2022.961027
work_keys_str_mv AT khaledimansoor covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT samenifatemeh covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT yahyazadesheida covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT radandishmaedeh covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT owliaparviz covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT bagherinader covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT afkhamihamed covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT mahjoormohamad covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT esmaelpourzahra covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT kohansalmaryam covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy
AT aghaeifarzad covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy

Ejemplares similares